RecruitingNCT04394871
Rare condition
Juvenile amyotrophic lateral sclerosis
1
studies recruiting now
as of 7 Sept 2026
2
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
20 May 2020
most recent study posted
among recruiting studies
Recruiting trials
Showing the 1 most recently updated recruiting study, as recorded 7 Sept 2026. Live status on each study page.
Search all Juvenile amyotrophic lateral sclerosis studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Juvenile amyotrophic lateral sclerosis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Juvenile amyotrophic lateral sclerosis
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (ALS2, SPG11, SIGMAR1, FUS, SPTLC1).
Treatments being studied
4 approved treatments and 125 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Tofersen (Qalsody)Approved: Edaravone (Radicava)Approved: Riluzole (Exservan)Approved: Mecobalamin (Asimil b-12)
Phase 3Quinidine
Phase 3Creatine
Phase 3Dolutegravir
Phase 3Ceftriaxone
Phase 3Masitinib (Kinavet)
Phase 3Taurolithocholic Acid
Phase 3Arimoclomol
Phase 3Dextromethorphan
+ 117 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).